18F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias.
Carl Taswell, Victor L Villemagne, Paul Yates...
https://pubmed.ncbi.nlm.nih.gov/26251415/Actively Recruiting
Led by Brain Health Alliance · Updated on 2026-10-06
20
Participants Needed
1
Research Sites
26 weeks
Total Duration
Researchers are evaluating the use of entire-body positron emission tomography PET scanners to improve the evaluation, monitoring, and measurement of both peripheral and central demyelination in patients with multiple sclerosis MS. This early phase 1 clinical trial focuses on comparing the uptake of the F18-florbetapir radiopharmaceutical in the nervous system of MS patients versus normal healthy subjects. The study aims to identify differences in radiotracer activity in myelinated, demyelinated, or remyelinated white matter using advanced PET-CT imaging technology. Participants will undergo entire-body PET-CT scans using state-of-the-art scanners from different manufacturers, including Siemens Biograph Vision and United Imaging uEXPLORER, among others. Amyvid F18-florbetapir will be administered to evaluate its binding in the white matter of the peripheral and central nervous system. The study includes parallel arms defined by the specific PET-CT scanner model used. Each participant completes a single PET-CT scan lasting between 10 and 20 minutes. During the study, psychological health will be monitored through questionnaires completed before and up to 90 days after participants are informed of their imaging results, if they choose to receive this information. Researchers will assess the primary outcome of entire-body PET imaging related to demyelination in the nervous system and monitor psychological health changes. The total participation involves a one-day imaging procedure with follow-up psychometric assessments over three months.
CONDITIONS
Entire-body PET Scans for Multiple Sclerosis
C
Carl Taswell, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Brain Health Alliance
Lead Sponsor
Center for Molecular Imaging & Therapy, Shreveport LA
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Siemens Biograph Vision PET‑CT (Amyvid) | United Imaging uEXPLORER PET‑CT (Amyvid) |
|---|---|---|
| What it is | Entire‑body PET‑CT imaging using Amyvid tracer with Siemens Biograph Vision scanner | Entire‑body PET‑CT imaging using Amyvid tracer with United Imaging uEXPLORER scanner |
| Role in trial | Investigational diagnostic scan using this specific scanner model | Investigational diagnostic scan using this specific scanner model |
| Primary use | Evaluate PET‑CT imaging of demyelination and myelin binding in MS and healthy subjects | Evaluate PET‑CT imaging of demyelination and myelin binding in MS and healthy subjects |
| How it is performed | Single entire‑body PET‑CT scan performed with Amyvid tracer using Siemens scanner | Single entire‑body PET‑CT scan performed with Amyvid tracer using United Imaging scanner |
| Evidence from outside this trial | Florbetapir PET imaging has shown ability to detect demyelination and monitor myelin loss in MS patients longitudinally | Florbetapir PET imaging has shown ability to detect demyelination and monitor myelin loss in MS patients longitudinally |
| Important risks | Not yet established in this study | Not yet established in this study |
| Important limitations | Pilot study with small sample size and exploratory design; performance may vary by scanner model | Pilot study with small sample size and exploratory design; performance may vary by scanner model |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 90 days
Participants undergo a single entire-body PET-CT scan lasting 10 to 20 minutes to evaluate nerve damage. Psychological health questionnaires are completed before and up to 90 days after the imaging results are shared with participants who choose to be informed.
1 imaging visit and follow-up questionnaires
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Carl Taswell, Victor L Villemagne, Paul Yates...
https://pubmed.ncbi.nlm.nih.gov/26251415/Brain Health Alliance
Lead Sponsor
Center for Molecular Imaging & Therapy, Shreveport LA
Collaborating Sponsor